National Cancer Institute (NCI)
NCI Public Inquiries Office
Building, 31, Room 10A03<br>31 Center Drive, MSC 2
Bethesda
Maryland
20892-2580
United States
Tel: 301-435-3848
Website: http://www.nci.nih.gov/
819 articles about National Cancer Institute (NCI)
-
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.
-
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here's how this consortium will help researchers.
-
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
2/3/2022
Castle Biosciences, Inc. today announced a collaboration with the National Cancer Institute (NCI) to link DecisionDx®-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program’s registries on cutaneous melanoma (CM) cases.
-
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
1/11/2022
Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.
-
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.
-
Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma
11/9/2021
Strand Therapeutics today announced that the company was awarded a Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI)
-
Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
5/27/2021
Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH)
-
Geisinger awarded $3.6 million to study genetics of cancer
4/29/2021
Contract with National Cancer Institute will leverage data from Geisinger's MyCode Community Health Initiative
-
BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Institute
8/4/2020
BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma. The study, expected to start later this year, will be the first in patients to eva
-
T-Cure Bioscience Signs Exclusive Worldwide License With NCI for the Development of T Cell Receptor Therapy for Treatment of Solid Tumors
4/8/2020
T-Cure Bioscience, Inc. announced that the Company has entered into an exclusive, worldwide license with the National Cancer Institute for intellectual property related to a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, for the treatment of KK-LC-1-expressing malignancies, such as gastric, lung, and breast cancers.
-
EicOsis Awarded SBIR Grant from the NCI/NIH to Evaluate the Potential of Drug Candidate, EC5026, to Treat Cancer-associated Pain
10/30/2019
EC5026 is an orally active potent small molecule that has been shown to be highly efficacious for pain relief of both inflammatory and neuropathic pain in a variety of animal species.
-
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
10/17/2019
Rafael will provide the compound for the study.
-
Aethlon Medical Receives National Cancer Institute Contract Award
9/16/2019
$1.86 Million Over Two Years to Develop Device for Isolating Exosomes
-
Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program
9/10/2019
Kindred Biosciences, Inc. announced that it has been selected by the National Cancer Institute as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program: Current Good Manufacturing Practice Production of Vaccines and Biologicals for Cancer Prevention.
-
RCCA Oncologists Help Write History with NCI's Recognition of John Theurer Cancer Center at Hackensack Meridian Health
7/24/2019
When the National Cancer Institute accorded the John Theurer Cancer Center – part of Hackensack Meridian Health Hackensack University Medical Center – a rare and important designation this May, the move represented two historic firsts.
-
BostonGene Announces Partnership with National Institutes of Health
7/23/2019
Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment
-
The declining impact of federal funding on cancer innovation
7/9/2019
The National Cancer Institute (NCI), an independent institute of the National Institutes of Health (NIH), was established in 1937 to provide for, foster and coordinate research relating to cancer.
-
AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing
5/29/2019
AgilVax, Inc. announced that the company has triggered Phase II funding of $2 million from its Fast Track Small Business Innovation Research grant awarded by the National Cancer Institute.
-
The White House budget proposal released earlier this week that slashed spending on the National Institutes of Health and Medicare programs has put members of the administration, including Health and Human Services Secretary Alex Azar on the defensive.
-
National Cancer Institute Director Norman “Ned” Sharpless will take over the role as acting commissioner of the FDA while the White House seeks a permanent replacement for the outgoing Scott Gottlieb.